Buscopan, antispasmodic agent
Antipyretic, anti-inflammatory, sedative
N-butylscopolamine bromide – 4 mg
Metamizole sodium – 500 mg
Phenol – 5 mg
Buscopan® Compositum contains the antispasmodic agent N-butylscopolamine bromide and the nonsteroidal anti-inflammatory drug Metamizole (NSAID).
Buscopan® Compositum has antispasmodic effects on the gastrointestinal tract and urogenital system.
N-butylscopolamine bromide is a quaternary ammonium derivative of scopolamine. This compound is an antagonist of acetylcholine activity on M-cholinoreceptors and also has some activity on nicotinic receptors. Its pharmacological properties are similar to the main representative of this class of drugs, atropine (such as antispasmodic properties, increase in heart rate, suppression of salivary and lacrimal secretion). After parenteral administration, N-butylscopolamine bromide is mainly excreted in the urine (about 54%).
Metamizole has anti-inflammatory, analgesic and antipyretic effects. Its mechanism of action, like other NSAIDs, is associated with inhibition of prostaglandin synthesis. In addition, it is an antagonist of bradykinin and histamine.
After intravenous administration it is mainly excreted with urine (50-70% depending on animal species).
Buscopan® Compositum is indicated in the treatment of abdominal pain associated with spastic colic.
Buscopan® compositum does not mask symptoms in cases of surgical colic and does not cause intestinal paralysis.
Buscopan® Compositum is used in the treatment of diarrhea in calves; it reduces pain and normalizes intestinal function by reducing peristalsis.
Hypersensitivity, arrhythmias, heart failure, gateway stenosis, glaucoma, nonspecific ulcerative colitis.
Side effects (frequency and severity):
A slight and transient increase in heart rate may occur in horses due to the parasympathetic activity of N-butylscopolamine bromide.
Use during pregnancy and lactation:
Laboratory studies in rats and rabbits have shown no obvious teratogenic effects. The drug may be used during pregnancy in usual doses.
Interaction with other drugs:
The effects of N-butylscopolamine bromide or methamisole may be potentiated by concomitant use of other anticholinergic and analgesic agents. Although specific interactions have not been described, administration of other anticholinergic drugs is contraindicated.
Doses and routes of administration:
Buscopan® Compositum is administered at a single dose of 0.2 mg N-butylscopolamine bromide and 25 mg methamisole / 2.2lb (1kg) body weight. This corresponds to 5 ml of injectable solution/220lb (100kg) body weight intravenously.
After intravenous injection Buscopan® Compositum spasmolytic effect occurs 2-5 minutes after injection and lasts for 4-6 hours. A single injection is usually sufficient to achieve significant improvement and reduce spasm and pain. If necessary, Buscopan® Compositum may be re-injected 4-6 hours later.
Buscopan® Compositum is administered at a dose of 0.4 mg N-butylscopolamine bromide and 50 mg metamisole/kg body weight at 12-hour intervals for up to three days by intravenous or intramuscular injection. A single dose corresponds to 1 mL of injectable solution/ 22lb (10 kg) body weight intravenously.
The toxicity of both components is very low. Toxicity studies in rats have shown non-specific symptoms such as ataxia, mydriasis, tachycardia, prostration, convulsions, coma and respiratory symptoms.
Antidotes: Physostigmine for N-butylscopolamine bromide. There are no specific antidotes for methamisole. In case of overdose, symptomatic therapy is necessary.
Special warnings for each animal species:
Unused vial: 4 years
After first use: 6 months
Store below 86F – (30°C).
Buscopan® Compositum is available in amber-colored glass vials containing 100 ml of solution for injection. Each bottle is packed in a cardboard box.
BERINGER INGELHAIM, Germany.